Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT LAWRENCE FLEISCHAUER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1285789065
CMS profile
57953
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$84.25

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $84.25 4

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $30.76 1
ARRAY BIOPHARMA INC $19.62 1
Sirtex Medical Inc $17.48 1
ABBVIE INC. $16.39 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT LAWRENCE FLEISCHAUER

NPI 1285789065 · CMS profile ID 57953

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285789065?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285789065?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285789065?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1285789065?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $84.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARRAY BIOPHARMA INC $19.6209/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132135089 CMS
ABBVIE INC. $16.3909/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103735553 CMS
Novartis Pharmaceuticals Corporation $30.7605/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086949515 CMS
Sirtex Medical Inc $17.4802/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142714648 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $76.24 8
PY2020 $18.82 2
PY2021 $2,731.92 3
PY2022 $1,144.93 5
PY2023 $23.72 1
PY2024 $84.25 4
PY2025 $290.60 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $82,946.55 11
PY2022 Principal investigator $30,457.88 33
PY2021 Principal investigator $116,928.89 44
PY2020 Recipient $656.00 1
PY2020 Principal investigator $144,873.80 55
PY2019 Recipient $3,698.00 1
PY2019 Principal investigator $153,312.17 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $390.00 12/24/2019 Non-covered Recipient Entity
US ONC RESEARCH LLC
Prospective Observational Study of Onpro vs SOC No dispute reported 06/30/2026 675778647
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $8,500.00 12/23/2019 Non-covered Recipient Entity
Us Oncology Research Llc
Single arm study with Regorafenib and Nivolumab in MSS CRC No dispute reported 06/30/2026 629166407
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 11/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673103725
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 11/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673104347
Principal investigator 1 Incyte Corporation $22.80 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518929
Principal investigator 1 Incyte Corporation $0.48 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518931
Principal investigator 1 Incyte Corporation $0.90 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518935
Principal investigator 1 Incyte Corporation $176.00 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518937
Principal investigator 1 Incyte Corporation $22.80 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518979
Principal investigator 1 Incyte Corporation $65.88 11/08/2019 Non-covered Recipient Entity
MCKESSON SPECIALTY PHARMACY LP
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666518985
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,060.00 11/05/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639761517
Principal investigator 1 Incyte Corporation $850.00 10/15/2019 Non-covered Recipient Entity
TX ONC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666457797
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 10/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673102465
Principal investigator 1 PFIZER INC. $7,370.00 10/04/2019 Non-covered Recipient Entity
US Oncology Research LLC
PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER No dispute reported 06/30/2026 671660227
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 09/19/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY ARLINGTON SOUTH
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive TPS 50 No dispute reported 06/30/2026 691367293
Principal investigator 1 Incyte Corporation $489.00 09/15/2019 Non-covered Recipient Entity
TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666487609
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673101944
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673102085
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $60.00 08/15/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639761513
Principal investigator 1 Incyte Corporation $850.00 07/15/2019 Non-covered Recipient Entity
TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666487607
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 07/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673102195
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,779.20 07/12/2019 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 639761507
Principal investigator 1 Incyte Corporation $32.00 06/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.- MCALLEN
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666511373
Principal investigator 1 Incyte Corporation $22.08 06/10/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.- MCALLEN
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666511385
Principal investigator 1 Genentech, Inc. $104.00 05/21/2019 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681079703
Principal investigator 1 Genentech, Inc. $52.00 05/21/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681085833
Principal investigator 1 Genentech, Inc. $130.00 05/21/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681090941
Principal investigator 1 Genentech, Inc. $26.00 05/21/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681091613
Principal investigator 1 Genentech, Inc. $136.60 05/21/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681093099
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $256.00 05/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673098307
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,756.00 05/01/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 639761515
Principal investigator 1 Incyte Corporation $361.00 04/15/2019 Non-covered Recipient Entity
TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666487589
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 04/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiationand as maintenance therapy versus chemoradiation alone in subjects with locally advancedhead and neck squamous cell carcinoma No dispute reported 06/30/2026 691305938
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 04/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673097711
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 04/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673098203
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 04/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673098615
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 04/15/2019 Non-covered Recipient Entity
Texas Oncology Southwest Fort Worth Pet
PCYC-1134M-CA No dispute reported 06/30/2026 673098789
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,089.84 04/10/2019 Non-covered Recipient Entity
Us Oncology Res Llc
Studying Interventions for Managing Patients With Chronic Myeloid Leukemia CML in Chronic Phase The 5-Year Prospective Cohort Study SIMPLICITY No dispute reported 06/30/2026 639761505
Principal investigator 1 Incyte Corporation $573.89 04/03/2019 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS-FAIRFAX
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666459903
Principal investigator 1 Incyte Corporation $5,279.08 04/03/2019 Non-covered Recipient Entity
VIRGINIA CANCER SPECIALISTS-FAIRFAX
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666459909
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,014.60 03/12/2019 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 639761509
Principal investigator 1 Eli Lilly and Company $27,967.00 03/12/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654298615
Principal investigator 1 Merck Sharp & Dohme Corporation $18.00 03/08/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiationand as maintenance therapy versus chemoradiation alone in subjects with locally advancedhead and neck squamous cell carcinoma No dispute reported 06/30/2026 691404063
Principal investigator 1 Amgen Inc. $18,000.00 02/26/2019 Non-covered Recipient Entity
US ONC RESEARCH LLC
Prospective Observational Study of Onpro vs SOC No dispute reported 06/30/2026 675795993
Principal investigator 1 Amgen Inc. $9,785.00 02/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Prospective Observational Study of Onpro vs SOC No dispute reported 06/30/2026 675793904
Principal investigator 1 Celgene Corporation $2,380.00 02/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Celgene - Connect MM No dispute reported 06/30/2026 675419121
Principal investigator 1 Incyte Corporation $489.00 02/15/2019 Non-covered Recipient Entity
TX ONC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666457789
Recipient Eli Lilly and Company $3,698.00 01/22/2019 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654283705
Principal investigator 1 Genentech, Inc. $7,872.80 01/21/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 681093097
Principal investigator 1 Eli Lilly and Company $0.13 01/17/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654297385
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,150.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 639761511
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,620.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
SUSTAIN, event driven trial No dispute reported 06/30/2026 639761519
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,334.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices No dispute reported 06/30/2026 639761521
Principal investigator 1 Eli Lilly and Company $24,251.04 01/15/2019 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 654297643
Principal investigator 1 Incyte Corporation $850.00 01/15/2019 Non-covered Recipient Entity
TX ONCOLOGY-BEAUMONT, MAMIE MCFADDIN WARD CANCER CENTER
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS MF OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA ET OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 666487641
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673093483
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 01/15/2019 Non-covered Recipient Entity
Texas Oncology, P.A.
PCYC-1134M-CA No dispute reported 06/30/2026 673093543
Principal investigator 1 Eli Lilly and Company $5,000.00 01/14/2019 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 No dispute reported 06/30/2026 654297809